Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 9, 2024
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries. The filing reports on the execution of a share repurchase programme initiated on August 7, 2024, which is part of a broader DKK 20 billion programme authorized for a 12-month period beginning February 6, 2024.
Key Financial Metrics and Transaction Details
This filing focuses on capital allocation via share buybacks rather than operational financial performance. Key metrics include:
- Specific Programme (Aug 7 - Nov 4, 2024): Authorized up to DKK 2.4 billion.
- Transactions Reported (Sep 2 - Sep 6, 2024): 212,000 B shares repurchased.
- Transaction Value (Sep 2 - Sep 6): DKK 192,605,871.
- Average Purchase Price (Sep 2 - Sep 6): Ranged between DKK 885.28 and DKK 933.58.
- Cumulative Repurchases (Since Feb 6, 2024): 12,023,313 B shares.
- Total Value Repurchased (Since Feb 6, 2024): DKK 10,592,256,521.
- Average Price (Since Feb 6, 2024): DKK 880.98 per B share.
- Treasury Shares Held: 13,351,944 B shares (0.3% of share capital).
Material Changes
The filing details the progression of the share repurchase programme. Since the last announcement, the company has accumulated an additional 212,000 B shares under the specific August 7 programme, bringing the total accumulated under that specific tranche to 956,187 shares. The total treasury share count has increased to 13,351,944 shares.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during the 12-month period beginning February 6, 2024. As of September 6, 2024, approximately 53% of the total authorized amount (DKK 10.59 billion of DKK 20 billion) has been utilized.
Risks and Contingencies: The filing does not disclose new operational risks or contingencies. It notes that the repurchases are conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining authorization under the DKK 20 billion programme (approx. DKK 9.4 billion remaining).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average purchase price of DKK 880.98.
- Review the full transaction history on novonordisk.com for daily repurchase details.
- Check the impact of the 0.3% treasury share holding on earnings per share (EPS) calculations in future reports.